BibTex RIS Kaynak Göster

-

Yıl 2013, , 53 - 57, 01.10.2015

Elif Kılıç Kan , Gülçin Cengiz Ecemiş Çiğdem Tura Bahadır Ayşegül Atmaca Hulusi Atmaca Ramis Çolak

https://doi.org/10.5472/MMJ.2013.02698.1

Öz

Acromegaly is a chronic disease characterized by the elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels. Treatment options for acromegaly are surgery, radiotherapy and medical treatments. Somatostatin analogues, dopamine agonists and pegvisomant are the options for medical treatment. Pegvisomant is a GH receptor antagonist that shows its effect by blocking GH receptor dimerization and the intracellular pathways required for the release of IGF-1. Pegvisomant is used as a third line treatment option, if biochemical improvement cannot be achieved despite surgery and maximum doses of other medical treatments. In this review, we will present acromegaly patients who recieved pegvisomant in our clinic, in light of the current literature

Anahtar Kelimeler

Acromegaly Pegvisomant Growth hormone receptor antagonist

Kaynakça

  • 1. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102. doi: 10.1111/j.1365-2265.1994.tb03789.x
  • 2. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41.
  • 3. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009;94:1509-17. doi: 10.1210/jc.2008-2421
  • 4. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002;23:623-46. doi: 10.1210/Fer.2001-0022
  • 5. Higham CE, Trainer PJ. Growth hormone excess and the development of growth hormone receptor antagonists. Exp Physiol 2008;93:1157- 69. doi: 10.1113/expphysiol.2008.042515
  • 6. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: Predictive value of serial insuline growth factor 1 measurements. J Clin Endocrinol Metab 2004;89:2789-96.
  • 7. Trainer PJ, Drake WM, Katznelson L. Treatment of acromegaly with the growth hormone reseptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7. doi: 10.1056/NEJM200004203421604 8. Trainer PJ. ACROSTUDY: the first five years. Eur J Endocrinol 2009;161:19-24.
  • 9. Van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9. doi: 10.1016/S0140-6736(01)06844-1
  • 10. Jimenez C, Burman P, Abs R, et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 2008; 159:517-23. doi: 10.1530/EJE- 08-0205
  • 11. Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growthhormone secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 2010;95:552-8. doi: 10.1210/jc.2009-1239
  • 12. Van der Lely AJ, Biller BM, Brue T, et al. Long term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97:1589-97. doi: 10.1210/jc.2011-2508
  • 13. Clemmons DR. The relatives roles of growth hormone and IGF-1 in controlling insülin sensitivity. J Clin Invest 2004;113:25-7. doi: 10.1172/JCI20660
  • 14. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005;90:5684-91. doi: 10.1210/jc.2005-0331
  • 15. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156:75-82. doi: 10.1530/ eje.1.02312
  • 16. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008; 93:3515-8. doi: 10.1210/jc.2008-0833
  • 17. Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 2011;21:129–33. doi: 10.1016/j.ghir.2011.03.004
  • 18. Bernabeu I, Marazuela M, Lucas T, et al. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome. J Clin Endocrinol Metab 2010;95:2147–54. doi: 10.1210/ jc.2009-2547
  • 19. Neggers SJ, Van der Lely AJ. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol 2009;5:546- 52. doi: 10.1038/nrendo.2009.175
  • 20. Van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9. doi: 10.1016/S0140-6736(01)06844-1
  • 21. Neggers SJ, de Herder WW, Feelders RA, Van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with longacting somatostatin analogs, in controlled acromegaly patients. Pituitary 2011;14:253-8. doi: 10.1007/s11102-010-0289-5
  • 22. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004;114:349–56. doi: 10.1172/ JCI200419933
  • 23. Rubeck KZ, Madsen M, Andreasan CM, Fisker S, Frystyk J, Jorgansen JO. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur J Endocrinol 2010;163:717-26. doi: 10.1530/EJE-10-0640
  • 24. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;93:3853- 9. doi: 10.1210/jc.2008-0669
  • 25. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, Van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009;160:529- 33. doi: 10.1530/EJE-08-0843
  • 26. Neggers SJ, Van Aken MO, Janssen JA, Feelders RA, de Herder WW, Van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegv

Pegvisomant tedavisi sonuçlarımız ve literatürün gözden geçirilmesi

Yıl 2013, , 53 - 57, 01.10.2015

Elif Kılıç Kan , Gülçin Cengiz Ecemiş Çiğdem Tura Bahadır Ayşegül Atmaca Hulusi Atmaca Ramis Çolak

https://doi.org/10.5472/MMJ.2013.02698.1

Öz

Akromegali, artmış büyüme hormonu (BH) sekresyonu ve artmış insülin benzeri büyüme hormonu-1 (IGF-1) seviyeleri ile karakterize kronik bir hastalıktır. Akromegalide tedavi seçenekleri cerrahi, radyoterapi ve medikal tedavidir. Medikal tedavide somatostatin analogları, dopamin agonistleri ve pegvisomant kullanılmaktadır. Pegvisomant, büyüme hormonu reseptör antagonisti olup etkisini reseptör dimerizasyonunun engellenmesi ile birlikte IGF-1 salınımı için gerekli intraselüler yolakları engelleyerek gösterir. Cerrahi ve maksimum doz ve kombinasyonda medikal tedaviye rağmen biyokimyasal yanıt sağlanamayan hastalarda üçüncü basamak tedavide kullanılır. Bu derlemede, akromegali tedavisinde diğer seçeneklere göre nispeten yeni olan pegvisomant tedavisi kliniğimizdeki tedavi sonuçlarımız ile birlikte güncel literatür ışığında tekrar gözden geçirilmiştir.

Anahtar Kelimeler

Akromegali Pegvisomant Büyüme hormonu reseptör antagonisti

Kaynakça

  • 1. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102. doi: 10.1111/j.1365-2265.1994.tb03789.x
  • 2. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41.
  • 3. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009;94:1509-17. doi: 10.1210/jc.2008-2421
  • 4. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002;23:623-46. doi: 10.1210/Fer.2001-0022
  • 5. Higham CE, Trainer PJ. Growth hormone excess and the development of growth hormone receptor antagonists. Exp Physiol 2008;93:1157- 69. doi: 10.1113/expphysiol.2008.042515
  • 6. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: Predictive value of serial insuline growth factor 1 measurements. J Clin Endocrinol Metab 2004;89:2789-96.
  • 7. Trainer PJ, Drake WM, Katznelson L. Treatment of acromegaly with the growth hormone reseptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7. doi: 10.1056/NEJM200004203421604 8. Trainer PJ. ACROSTUDY: the first five years. Eur J Endocrinol 2009;161:19-24.
  • 9. Van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9. doi: 10.1016/S0140-6736(01)06844-1
  • 10. Jimenez C, Burman P, Abs R, et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 2008; 159:517-23. doi: 10.1530/EJE- 08-0205
  • 11. Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growthhormone secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 2010;95:552-8. doi: 10.1210/jc.2009-1239
  • 12. Van der Lely AJ, Biller BM, Brue T, et al. Long term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97:1589-97. doi: 10.1210/jc.2011-2508
  • 13. Clemmons DR. The relatives roles of growth hormone and IGF-1 in controlling insülin sensitivity. J Clin Invest 2004;113:25-7. doi: 10.1172/JCI20660
  • 14. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005;90:5684-91. doi: 10.1210/jc.2005-0331
  • 15. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156:75-82. doi: 10.1530/ eje.1.02312
  • 16. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008; 93:3515-8. doi: 10.1210/jc.2008-0833
  • 17. Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 2011;21:129–33. doi: 10.1016/j.ghir.2011.03.004
  • 18. Bernabeu I, Marazuela M, Lucas T, et al. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome. J Clin Endocrinol Metab 2010;95:2147–54. doi: 10.1210/ jc.2009-2547
  • 19. Neggers SJ, Van der Lely AJ. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol 2009;5:546- 52. doi: 10.1038/nrendo.2009.175
  • 20. Van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9. doi: 10.1016/S0140-6736(01)06844-1
  • 21. Neggers SJ, de Herder WW, Feelders RA, Van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with longacting somatostatin analogs, in controlled acromegaly patients. Pituitary 2011;14:253-8. doi: 10.1007/s11102-010-0289-5
  • 22. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004;114:349–56. doi: 10.1172/ JCI200419933
  • 23. Rubeck KZ, Madsen M, Andreasan CM, Fisker S, Frystyk J, Jorgansen JO. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur J Endocrinol 2010;163:717-26. doi: 10.1530/EJE-10-0640
  • 24. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;93:3853- 9. doi: 10.1210/jc.2008-0669
  • 25. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, Van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009;160:529- 33. doi: 10.1530/EJE-08-0843
  • 26. Neggers SJ, Van Aken MO, Janssen JA, Feelders RA, de Herder WW, Van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegv
Toplam 25 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Derleme
Yazarlar

Elif Kılıç Kan

Gülçin Cengiz Ecemiş Bu kişi benim

Çiğdem Tura Bahadır Bu kişi benim

Ayşegül Atmaca Bu kişi benim

Hulusi Atmaca Bu kişi benim

Ramis Çolak Bu kişi benim

Yayımlanma Tarihi 1 Ekim 2015
Yayımlandığı Sayı Yıl 2013

Kaynak Göster

APA Kılıç Kan, E., Cengiz Ecemiş, G., Tura Bahadır, Ç., Atmaca, A., vd. (2015). Pegvisomant tedavisi sonuçlarımız ve literatürün gözden geçirilmesi. Marmara Medical Journal, 26(2), 53-57. https://doi.org/10.5472/MMJ.2013.02698.1
AMA Kılıç Kan E, Cengiz Ecemiş G, Tura Bahadır Ç, Atmaca A, Atmaca H, Çolak R. Pegvisomant tedavisi sonuçlarımız ve literatürün gözden geçirilmesi. Marmara Med J. Ekim 2015;26(2):53-57. doi:10.5472/MMJ.2013.02698.1
Chicago Kılıç Kan, Elif, Gülçin Cengiz Ecemiş, Çiğdem Tura Bahadır, Ayşegül Atmaca, Hulusi Atmaca, ve Ramis Çolak. “Pegvisomant Tedavisi sonuçlarımız Ve literatürün gözden geçirilmesi”. Marmara Medical Journal 26, sy. 2 (Ekim 2015): 53-57. https://doi.org/10.5472/MMJ.2013.02698.1.
EndNote Kılıç Kan E, Cengiz Ecemiş G, Tura Bahadır Ç, Atmaca A, Atmaca H, Çolak R (01 Ekim 2015) Pegvisomant tedavisi sonuçlarımız ve literatürün gözden geçirilmesi. Marmara Medical Journal 26 2 53–57.
IEEE E. Kılıç Kan, G. Cengiz Ecemiş, Ç. Tura Bahadır, A. Atmaca, H. Atmaca, ve R. Çolak, “Pegvisomant tedavisi sonuçlarımız ve literatürün gözden geçirilmesi”, Marmara Med J, c. 26, sy. 2, ss. 53–57, 2015, doi: 10.5472/MMJ.2013.02698.1.
ISNAD Kılıç Kan, Elif vd. “Pegvisomant Tedavisi sonuçlarımız Ve literatürün gözden geçirilmesi”. Marmara Medical Journal 26/2 (Ekim 2015), 53-57. https://doi.org/10.5472/MMJ.2013.02698.1.
JAMA Kılıç Kan E, Cengiz Ecemiş G, Tura Bahadır Ç, Atmaca A, Atmaca H, Çolak R. Pegvisomant tedavisi sonuçlarımız ve literatürün gözden geçirilmesi. Marmara Med J. 2015;26:53–57.
MLA Kılıç Kan, Elif vd. “Pegvisomant Tedavisi sonuçlarımız Ve literatürün gözden geçirilmesi”. Marmara Medical Journal, c. 26, sy. 2, 2015, ss. 53-57, doi:10.5472/MMJ.2013.02698.1.
Vancouver Kılıç Kan E, Cengiz Ecemiş G, Tura Bahadır Ç, Atmaca A, Atmaca H, Çolak R. Pegvisomant tedavisi sonuçlarımız ve literatürün gözden geçirilmesi. Marmara Med J. 2015;26(2):53-7.